ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±ÂÞ¶¬ÁᣩÒûʳÒòËØÓëÈËÀ࿵½¡Ç×½üÏà¹Ø¡£½üÄêÀ´·¢Ã÷£¬£¬£¬À±½·ÉãÈë¾ßÓжàÖÖÐÄѪ¹Ü»ñÒæ£¬£¬£¬Í¨ÀýÉãÈëÀ±½·ÓÐÖúÓÚ½µµÍÐÄѪ¹Ü¼²²¡µÄéæÃü·çÏÕ¡£×÷ΪÐÄѪ¹Ü¼²²¡µÄÖ÷ҪΣÏÕÒòËØ£¬£¬£¬Ñª¹Ü¸Æ»¯ÓëÀ±½·ÉãÈëµÄ¹ØÏµÉв»Ã÷È·¡£
3ÔÂ2ÈÕ£¬£¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚ°ËÒ½Ôº»Æ»Ô½ÌÊÚÍŶÓÔÚHypertension£¨IF 10.19£©½ÒÏþÁËÌâΪ¡°Capsaicin Attenuates Arterial Calcification Through Promoting SIRT6-Mediated Deacetylation and Degradation of Hif1¦Á (Hypoxic-Inducible Factor-1 Alpha)¡±µÄÎÄÕ£¬£¬£¬Ê×´ÎÌá³öÀ±½·ÉãÈë¶ÔѪ¹Ü¸Æ»¯µÄÔ¤·À±£»£»£»¤×÷Ó㬣¬£¬ÎªÖÎÁÆÑª¹Ü¸Æ»¯ÌṩÁËÐÂ˼Ð÷¡£
ÔÚ¸ÃÑо¿ÖУ¬£¬£¬×÷Õß·¢Ã÷£¬£¬£¬À±½·ÉãÈëÕߵĹÚÂö¸Æ»¯»ý·ÖÏÔÖøµÍÓÚ·ÇÉãÈëÕß¡£²¢ÇÒÀ±½·ÉãÈëÕßÔÚËæ·ÃÀú³ÌÖÐÕ¹ÏÖ³ö¸üÉٸƻ¯Ï£Íû¸ºµ£¡£¡£¡£Ëæ×ÅÀ±½·ÉãÈëÁ¿µÄÔöÌí£¬£¬£¬Ñª¹Ü¸Æ»¯»ý·ÖˮƽÖð½¥½µµÍ¡£Í¬Ê±¶¯ÎPϸ°ûʵÑéÖнøÒ»²½Õ¹ÏÖÀ±½·ËضÔѪ¹Ü¸Æ»¯µÄ±£»£»£»¤×÷ÓúͻúÖÆ¡£Ôڸƻ¯Ä£×ÓÖУ¬£¬£¬SIRT6±í´ïïÔÌ£¬£¬£¬È±ÑõÓÕµ¼Òò×ÓHif1¦ÁÎȹÌÐÔÔöÌí£¬£¬£¬µ¼ÖÂѪ¹Üƽ»¬¼¡Ï¸°ûÏò³É¹Ç±íÐÍת»¯¡£¶øÀ±½·ÉãÈë¿É¼¤»î1ÐÍ˲ʱ¸ÐÊÜÆ÷µçλÏã²ÝËØ£¨transient receptor potential vanilloid type 1£¬£¬£¬TRPV1£©£¬£¬£¬½ø¶øÉϵ÷SIRT6£¬£¬£¬Ôö½øHif1¦ÁÈ¥ÒÒõ£»£»£»¯¼°½µ½â£¬£¬£¬ÒÖÖÆÑª¹Üƽ»¬¼¡Ï¸°û³É¹Ç±íÐÍת»¯£¬£¬£¬Ê©Õ¹Ñª¹Ü¸Æ»¯µÄ±£»£»£»¤×÷Óá£

Ѫ¹Ü¸Æ»¯ÊÇÐÄÄÔѪ¹Ü¼²²¡¸ß·¢²¡Âʼ°¸ßéæÃüÂʵÄÖ÷ҪΣÏÕÒòËØ£¬£¬£¬µ«ÓÉÓÚÆä±¬·¢ÆøÖÆÖش󣬣¬£¬ÏÖÔÚÉÐÎÞÓÐÓõÄÖÎÁÆÊֶΡ£¶øÔÚ±¾Ñо¿ÖУ¬£¬£¬»Æ»Ô½ÌÊÚÍŶӷ¢Ã÷£¬£¬£¬À±½·ËØ¿ÉÒÖÖÆÑª¹Üƽ»¬¼¡Ï¸°û³É¹Ç±íÐÍת»¯£¬£¬£¬¼õÇáѪ¹Ü¸Æ»¯¡£ÕâÒ»Ö÷Òª·¢Ã÷²»µ«Ú¹ÊÍÁËÀ±½·ÉãÈë½µµÍÐÄѪ¹Ü¼²²¡éæÃü·çÏÕµÄDZÔÚ»úÀí£¬£¬£¬Ò²ÎªÑª¹Ü¸Æ»¯ÌṩÁËеÄÖÎÁưе㼰ÖÎÁÆÀíÄî¡£
¸ÃÊÂÇéÓÉngµç×ÓÓÎϷΪ×ÔÁ¦Íê³Éµ¥Î»£¬£¬£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚ°ËÒ½Ôº²©Ê¿ÉúÂÞ¶¬ÁáºÍÀèÎÄÐÅΪ²¢ÁеÚÒ»×÷Õߣ¬£¬£¬ÂÛÎÄ×ÔÁ¦Í¨Ñ¶×÷Õ߻ƻԽÌÊÚ¶àÄêÀ´Ò»Ö±ÖÂÁ¦ÓÚѪ¹Ü¸Æ»¯¡¢¡¢¡¢Ñª¹ÜÐàÂõµÄÑо¿£¬£¬£¬×¢ÖØ»ù´¡ÓëÁÙ´²µÄת»¯Ó¦Óá£ÔÚ¸ßѪѹ£¬£¬£¬ÐÄÉö¶Ô»°ÐÂǰÑÔ£¬£¬£¬Ñ×ÐÔÐàÂõºÍ±í¹ÛÒÅ´«Ñ§·½Ã棬£¬£¬Ì½Ë÷¶¯Âö¸Æ»¯±¬·¢ÆøÖƺÍÁÙ´²×ª»¯£¬£¬£¬È¡µÃϵÁÐÁ¢ÒìÐÔЧ¹û£¬£¬£¬ÔÚ¸ÃÁìÓòÒѾ½ÒÏþÏà¹ØÑо¿Ð§¹û£¬£¬£¬°üÀ¨J Clin Invest£¨2021£¬£¬£¬2022£©¡¢¡¢¡¢Hypertension£¨2018£¬£¬£¬2021£¬£¬£¬2022£©¡¢¡¢¡¢Signal Transduct Target Ther¡¢¡¢¡¢Cell Death Differ¡¢¡¢¡¢TheranosticsºÍATVBµÈרҵÆÚ¿¯¡£
ÂÛÎÄÁ´½Ó: https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.121.18778